Patient choice data
When given the choice, 96% of participants selected APRETUDE over daily oral TDF/FTC in the HPTN 083 OLE1
*Patients were told the results of the blinded part of the study, and based on this information, they provided their reason for choosing the regimen at the time of the HPTN 083 OLE entry.
Most participants selected APRETUDE based on preference for a route of administration1
- Of those who chose TDF/FTC (n=33), the top reason given was “prefer pills and/or don’t like injections” (n=17)